Sephora M Tang1, Aylar Ansarian2, Darren B Courtney3. 1. Staff Psychiatrist, The Ottawa Hospital, Psychiatry Outpatient Department; University of Ottawa, Faculty of Medicine, Department of Psychiatry, Ottawa, Ontario. 2. Psychiatrist, Homewood Health Centre, Guelph, Ontario. 3. Staff Psychiatrist, Concurrent Disorder Youth Inpatient Unit, Centre for Addiction and Mental Health; Assistant Professor, Department of Psychiatry, University of Toronto, Toronto, Ontario.
Abstract
OBJECTIVES: To examine the association between clozapine treatment and frequency of cannabis use in adolescents with co-occurring psychotic and cannabis use disorder in a retrospective cohort chart review. METHOD: We conducted a retrospective cohort chart review of patients diagnosed with a psychotic disorder and concurrent cannabis use disorder admitted to a tertiary care youth inpatient unit from 2010-2012. Longitudinal exposure and outcome data was coded month-by-month. Frequency of cannabis use was measured using a 7-point ordinal scale. Severity of psychosis was measured on a 3-point ordinal scale. Mixed effects regression modeling was used to describe the relationship between exposure and outcome variables. RESULTS: Thirteen patients had exposure to clozapine and fourteen had no exposure to clozapine. Cannabis use decreased in patients treated with clozapine, compared to patients treated with other antipsychotics (OR 2.8; 95% CI 0.97-7.9). Compared to no medication, clozapine exposure was associated with significantly less cannabis use (OR 7.1; 95% CI 2.3-22.3). Relative to treatment with other antipsychotics, clozapine exposure was significantly associated with lower severity of psychotic symptoms (OR 3.7; 95% CI 1.2-11.8). CONCLUSIONS: Clozapine may lead to decreased cannabis use and psychotic symptoms in adolescents with concurrent psychosis and substance use. Clinical trials are warranted.
OBJECTIVES: To examine the association between clozapine treatment and frequency of cannabis use in adolescents with co-occurring psychotic and cannabis use disorder in a retrospective cohort chart review. METHOD: We conducted a retrospective cohort chart review of patients diagnosed with a psychotic disorder and concurrent cannabis use disorder admitted to a tertiary care youth inpatient unit from 2010-2012. Longitudinal exposure and outcome data was coded month-by-month. Frequency of cannabis use was measured using a 7-point ordinal scale. Severity of psychosis was measured on a 3-point ordinal scale. Mixed effects regression modeling was used to describe the relationship between exposure and outcome variables. RESULTS: Thirteen patients had exposure to clozapine and fourteen had no exposure to clozapine. Cannabis use decreased in patients treated with clozapine, compared to patients treated with other antipsychotics (OR 2.8; 95% CI 0.97-7.9). Compared to no medication, clozapine exposure was associated with significantly less cannabis use (OR 7.1; 95% CI 2.3-22.3). Relative to treatment with other antipsychotics, clozapine exposure was significantly associated with lower severity of psychotic symptoms (OR 3.7; 95% CI 1.2-11.8). CONCLUSIONS: Clozapine may lead to decreased cannabis use and psychotic symptoms in adolescents with concurrent psychosis and substance use. Clinical trials are warranted.
Authors: Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; Serge Beaulieu; Martin Alda; Claire O'Donovan; Glenda Macqueen; Roger S McIntyre; Verinder Sharma; Arun Ravindran; L Trevor Young; Roumen Milev; David J Bond; Benicio N Frey; Benjamin I Goldstein; Beny Lafer; Boris Birmaher; Kyooseob Ha; Willem A Nolen; Michael Berk Journal: Bipolar Disord Date: 2012-12-12 Impact factor: 6.744
Authors: N Dekker; J Meijer; M Koeter; W van den Brink; N van Beveren; R S Kahn; D H Linszen; J van Os; D Wiersma; R Bruggeman; W Cahn; L de Haan; L Krabbendam; I Myin-Germeys Journal: Psychol Med Date: 2012-03-27 Impact factor: 7.723
Authors: S Kumra; J A Frazier; L K Jacobsen; K McKenna; C T Gordon; M C Lenane; S D Hamburger; A K Smith; K E Albus; J Alaghband-Rad; J L Rapoport Journal: Arch Gen Psychiatry Date: 1996-12
Authors: Mary F Brunette; Ree Dawson; Christopher D O'Keefe; Meera Narasimhan; Douglas L Noordsy; Joanne Wojcik; Alan I Green Journal: J Dual Diagn Date: 2011
Authors: F M Leweke; D Piomelli; F Pahlisch; D Muhl; C W Gerth; C Hoyer; J Klosterkötter; M Hellmich; D Koethe Journal: Transl Psychiatry Date: 2012-03-20 Impact factor: 6.222
Authors: Karolina Kozak Bidzinski; Darby J E Lowe; Marcos Sanches; Maryam Sorkhou; Isabelle Boileau; Michael Kiang; Daniel M Blumberger; Gary Remington; Clement Ma; David J Castle; Rachel A Rabin; Tony P George Journal: Schizophrenia (Heidelb) Date: 2022-02-24